| human | Q5 |
| P496 | ORCID iD | 0000-0002-5173-4712 |
| P69 | educated at | University of Iowa College of Public Health | Q7895559 |
| P108 | employer | Mayo Clinic | Q1130172 |
| P735 | given name | Susan | Q14936243 |
| Susan | Q14936243 | ||
| P106 | occupation | researcher | Q1650915 |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q34340672 | A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. |
| Q40597341 | A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci |
| Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
| Q33515409 | A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia |
| Q36204229 | A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk |
| Q52726121 | A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia. |
| Q34881099 | A genome-wide association study of marginal zone lymphoma shows association to the HLA region |
| Q35669222 | A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. |
| Q24656746 | A genomewide association study of citalopram response in major depressive disorder |
| Q36384877 | A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia |
| Q29417093 | A mega-analysis of genome-wide association studies for major depressive disorder |
| Q28943487 | A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus |
| Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
| Q52582240 | A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. |
| Q46435901 | A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. |
| Q36306403 | A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region |
| Q61948755 | Abstract 3266: Expression quantitative trait locus analysis of triple negative breast cancer |
| Q59059958 | Abstract 5071: A genome-wide association study suggests evidence of variants at 6p21.32 associated with marginal zone lymphoma |
| Q59060123 | Abstract 5072: Meta-analysis of genome-wide association studies identifies novel susceptibility loci for follicular lymphoma |
| Q57610256 | Abstract LB-272: Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma |
| Q91590665 | Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare |
| Q37517160 | Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia |
| Q36645895 | Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women |
| Q93023303 | Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma |
| Q36122304 | An analytical workflow for accurate variant discovery in highly divergent regions |
| Q28139251 | An autosomal genomic screen for autism. Collaborative linkage study of autism |
| Q34584111 | Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample |
| Q24170413 | Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types |
| Q40834193 | Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia |
| Q37361805 | Analysis of the RNASEL gene in familial and sporadic prostate cancer |
| Q33332805 | Analysis of variation in NF-kappaB genes and expression levels of NF-kappaB-regulated molecules |
| Q60654493 | Antibiotic use during the first 200 days of life |
| Q97070156 | Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers |
| Q92431571 | Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis |
| Q99609984 | Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer |
| Q33913645 | Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder |
| Q52576610 | Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. |
| Q35251758 | Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women |
| Q37607304 | Associations between cigarette smoking, hormone therapy, and folate intake with incident colorectal cancer by TP53 protein expression level in a population-based cohort of older women |
| Q37170000 | Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women |
| Q36645906 | Associations between intake of folate and related micronutrients with molecularly defined colorectal cancer risks in the Iowa Women's Health Study |
| Q35860732 | Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement |
| Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
| Q28083556 | Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci |
| Q74129954 | Associations of pacifier use, digit sucking, and child care attendance with cessation of breastfeeding |
| Q96130488 | Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes |
| Q39154824 | Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). |
| Q33386533 | Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis |
| Q90995444 | Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre |
| Q37176527 | B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome |
| Q35004965 | BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q26787260 | Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis |
| Q92530019 | Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis |
| Q100457582 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk |
| Q37324992 | Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia |
| Q38848633 | CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia |
| Q34143223 | CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. |
| Q92337248 | CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation |
| Q37135341 | CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis |
| Q30784285 | Candidate-gene association studies with pedigree data: controlling for environmental covariates |
| Q47201239 | Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend |
| Q93338771 | Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts |
| Q38851252 | ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine: progresses and future directions |
| Q37004844 | Chronic lymphocytic leukaemia genetics overview |
| Q98192537 | Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci |
| Q60955786 | Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy |
| Q33558148 | Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes |
| Q36656445 | Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women |
| Q34042268 | Cigarette smoking and colorectal cancer risk by molecularly defined subtypes |
| Q92732959 | Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center |
| Q50099990 | Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. |
| Q96617300 | Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance |
| Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
| Q34253252 | Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families |
| Q36734692 | Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes |
| Q36141922 | Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia |
| Q37059754 | Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia |
| Q38838300 | Comparative analysis of de novo assemblers for variation discovery in personal genomes |
| Q28290530 | Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci |
| Q33333026 | Comparison of tagging single-nucleotide polymorphism methods in association analyses |
| Q91232504 | Comparison of tumor staging systems for cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia |
| Q33904602 | Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. |
| Q90751447 | Correction to: Infectious mononucleosis, immune genotypes, and non-Hodgkin lymphoma (NHL): an InterLymph Consortium study |
| Q47101456 | Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients |
| Q33598099 | Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. |
| Q37118775 | Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia |
| Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q34974058 | Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia |
| Q97588699 | Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma amongst chronic lymphocytic leukemia patients |
| Q35031964 | Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma |
| Q53280595 | Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. |
| Q33903379 | Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients |
| Q24612248 | Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing |
| Q98949804 | Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia |
| Q40533698 | Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. |
| Q36660850 | Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma. |
| Q73371925 | Effect of allelic heterogeneity on the power of the transmission disequilibrium test |
| Q36195016 | Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. |
| Q53639451 | Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. |
| Q35056309 | Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. |
| Q28393769 | Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project |
| Q35105482 | Evaluating the influence of quality control decisions and software algorithms on SNP calling for the affymetrix 6.0 SNP array platform |
| Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
| Q34020842 | Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects |
| Q37662238 | Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. |
| Q57150440 | Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22 |
| Q44686783 | Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q42332100 | FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. |
| Q38391516 | FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts |
| Q37007414 | Familial CLL: genes and environment |
| Q33938058 | Familial chronic lymphocytic leukemia |
| Q34702451 | Familial chronic lymphocytic leukemia: what does it mean to me? |
| Q34044984 | Familial predisposition and genetic risk factors for lymphoma |
| Q34142690 | Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene |
| Q35751046 | Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q35836638 | Food-frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphoma |
| Q33763482 | Functional and clinical significance of variants localized to 8q24 in colon cancer |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q33886166 | GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma |
| Q42975813 | Genetic diversity of newly diagnosed follicular lymphoma |
| Q42375830 | Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia |
| Q92588645 | Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes |
| Q34062500 | Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma |
| Q28296286 | Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs |
| Q53090976 | Genetic risk of chronic lymphocytic leukemia: a tale of two cities. |
| Q86775363 | Genetic susceptibility to chronic lymphocytic leukemia |
| Q33780771 | Genetic susceptibility variants for chronic lymphocytic leukemia |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q36447972 | Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma |
| Q37345560 | Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q37328297 | Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma |
| Q89737463 | Genetically Determined Height and Risk of Non-hodgkin Lymphoma |
| Q28393571 | Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes |
| Q79255959 | Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study |
| Q36934345 | Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy |
| Q36446270 | Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies |
| Q89467799 | Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia |
| Q37637724 | Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q29417100 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer |
| Q28943377 | Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL |
| Q34288685 | Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region |
| Q28943339 | Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia |
| Q28248768 | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma |
| Q34671809 | Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q34033939 | Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. |
| Q33198441 | Genome-wide linkage analysis of systolic blood pressure: a comparison of two approaches to phenotype definition |
| Q46183538 | Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project |
| Q30833823 | Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome |
| Q52646188 | Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. |
| Q34292891 | Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma |
| Q36650573 | Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma |
| Q54465029 | HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes. |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q37483454 | Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). |
| Q90699306 | History of autoimmune conditions and lymphoma prognosis |
| Q35626311 | Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. |
| Q91994319 | Host genetic variation in tumor necrosis factor and nuclear factor-κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study |
| Q91035311 | Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis |
| Q59360321 | Human Pegivirus infection and lymphoma risk and prognosis: a North American study |
| Q35985600 | Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes |
| Q90690187 | IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q64082120 | Identification of factors associated with duplicate rate in ChIP-seq data |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q33232704 | Identification of genes involved in alcohol consumption and cigarettes smoking |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q41485437 | Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. |
| Q35188629 | Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. |
| Q92213891 | Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma |
| Q39025763 | Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels |
| Q92339358 | Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma |
| Q31135473 | Impact of post-alignment processing in variant discovery from whole exome data |
| Q95657808 | Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice |
| Q34014125 | Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines |
| Q36033380 | Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma |
| Q46143500 | Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls |
| Q42219104 | Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication |
| Q89986810 | Infectious mononucleosis, immune genotypes, and non-Hodgkin lymphoma (NHL): an InterLymph Consortium study |
| Q34996647 | Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer |
| Q90631958 | Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways |
| Q52900050 | Investigating the numerical effects of ascertainment bias in linkage analysis: development of methods and preliminary results. |
| Q28253113 | Investigation of polymorphisms in the CREM gene in panic disorder |
| Q44820568 | Investigation of serotonin-related genes in antidepressant response |
| Q34282335 | LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis |
| Q36618819 | LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q31154947 | Linkage analysis using principal components of gene expression data. |
| Q89929962 | Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study |
| Q48304637 | Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. |
| Q57287569 | Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma |
| Q46737936 | Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma |
| Q44190356 | Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer. |
| Q36680976 | Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes |
| Q52048372 | Markov chain Monte Carlo linkage analysis: effect of bin width on the probability of linkage. |
| Q34137904 | Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project |
| Q34137942 | Medical history, lifestyle, family history, and occupational risk factors for adult acute lymphocytic leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project |
| Q34137880 | Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project |
| Q34137948 | Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project |
| Q34137888 | Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project |
| Q28393760 | Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project |
| Q34396112 | Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project |
| Q34137897 | Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project |
| Q36675182 | Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q34998866 | Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression |
| Q35212377 | Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q37219438 | Mutations in CHEK2 associated with prostate cancer risk |
| Q28205246 | No association of germline alteration of MSR1 with prostate cancer risk |
| Q57150535 | No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder |
| Q60414991 | No genetic linkage or association between a functional promoter polymorphism in the monoamine oxidase-A gene and panic disorder |
| Q35815614 | Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium |
| Q37591655 | Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium |
| Q28751388 | Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies |
| Q48124027 | Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. |
| Q45324330 | Outcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression |
| Q50118872 | Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. |
| Q85938416 | Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q36440086 | PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium |
| Q37532952 | Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis |
| Q30827643 | PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. |
| Q50639720 | Patterns of dietary fluoride supplement use during infancy. |
| Q73106462 | Patterns of fluoride dentifrice use among infants |
| Q36710788 | Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma |
| Q33326612 | Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample |
| Q39002032 | Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q36645889 | Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women |
| Q36645919 | Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women |
| Q52068482 | Power comparisons between the TDT and two likelihood-based methods. |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q91789709 | Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy |
| Q36354265 | Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study |
| Q110788200 | Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank |
| Q37402310 | Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q53174983 | Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. |
| Q34974698 | RVboost: RNA-seq variants prioritization using a boosting method |
| Q90242700 | Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice |
| Q37132380 | Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource |
| Q34137915 | Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project |
| Q92123921 | Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma |
| Q118696613 | Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era |
| Q40185340 | Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. |
| Q37472823 | Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study |
| Q42334355 | Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia |
| Q33960777 | Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response |
| Q46970944 | Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia |
| Q91370408 | Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics |
| Q24648778 | Risk of non-Hodgkin lymphoma in association with germline variation in complement genes |
| Q36822986 | Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis |
| Q90589559 | Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL) |
| Q28214420 | Role of HPC2/ELAC2 in hereditary prostate cancer |
| Q34430697 | Sequence analysis of the serotonin transporter and associations with antidepressant response |
| Q36194254 | Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans |
| Q36999599 | Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma |
| Q35847445 | Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia |
| Q36487605 | Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium |
| Q52808766 | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. |
| Q37552790 | Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia |
| Q33627714 | Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era |
| Q50311669 | Stoppage: an issue for segregation analysis. |
| Q84751096 | Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population |
| Q37004883 | Susceptibility genes and B-chronic lymphocytic leukaemia |
| Q90092036 | Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL |
| Q36879641 | The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma |
| Q36443311 | The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. |
| Q91538023 | The association of physical activity before and after lymphoma diagnosis with survival outcomes |
| Q43178455 | The efficacy of ibrutinib in the treatment of Richter syndrome |
| Q33332867 | The genetics of gene expression: comparison of linkage scans using two phenotype normalization methods |
| Q90429109 | The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice |
| Q35607281 | The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma |
| Q37098971 | The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia |
| Q33379107 | The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma |
| Q92888787 | The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor |
| Q92649921 | The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas |
| Q37082267 | Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma |
| Q33388795 | Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone |
| Q36054317 | Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort |
| Q91833083 | Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index |
| Q33741481 | Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium |
| Q57285472 | Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia |
| Q92994868 | Two truncating variants in FANCC and breast cancer risk |
| Q35569501 | Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Q37068125 | Validation of a new prognostic index for patients with chronic lymphocytic leukemia |
| Q46878572 | Variants in PDE11A and PDE1A are not associated with citalopram response |
| Q34667541 | Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia |
| Q34193968 | Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. |
| Q40070467 | Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. |
| Q83366101 | When the negative is positive |
| Q33701845 | Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma |
| Q36022544 | Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. |
Search more.